Guardant Health | 10-Q: Quarterly report
Guardant Health Stock Jumps 6.9% on Earnings Beat, Raised Guidance
Guardant Health Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance.
Guardant Health Raises 2025 View To Rev $880M-$890M >GH
Guardant Health Reports Q1 EPS (49c), Consensus (59c)
Earnings Flash (GH) Guardant Health Posts Q1 Revenue $203.5M, Vs. FactSet Est of $190.1M
Guardant Health | 8-K: Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Express News | Guardant Health Q1 Adjusted Net Income USD -61.1 Million Vs. IBES Estimate USD -94.3 Million
Press Release: Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Guardant Health 1Q Loss/Shr 77c >GH
Express News | Guardant Health Outlook FY Revenue USD 880-890 Million
Express News | Guardant Health Q1 Revenue USD 203.5 Million Vs. IBES Estimate USD 190.1 Million
Express News | Guardant Health Q1 Adjusted EPS USD -0.49 Vs. IBES Estimate USD -0.81
CCORF Maintains Guardant Health(GH.US) With Buy Rating
Unusual Options Activity: BKNG, SMCI and Others Attract Market Bets, BKNG V/OI Ratio Reaches 66.3
Guardant Health's Shield Test Shows Promise in MCED Market Despite Challenges
Guardant Health Presents Data From Study Showing That Methylation-Based Shield MCD Test Showed High Specificity And Clinically Meaningful Sensitivity Across Ten Tumor Types
Guardant Health (GH) Q1 Earnings Report Preview: What To Look For
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Unusual Options Activity: CRM, MRK and Others Attract Market Bets, CRM V/OI Ratio Reaches 231.7